Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned a consensus rating of “Hold” from the sixteen analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $30.70.

HIMS has been the topic of a number of recent research reports. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen dropped their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Weiss Ratings downgraded Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 price target on shares of Hims & Hers Health in a research note on Tuesday, May 5th.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 4,490 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the transaction, the insider directly owned 6,790 shares in the company, valued at $213,885. This trade represents a 39.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock worth $2,711,339 in the last 90 days. Insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the period. SG Americas Securities LLC lifted its position in Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after purchasing an additional 75,679 shares during the period. Vanguard Group Inc. lifted its position in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. Munich Reinsurance Co Stock Corp in Munich purchased a new stake in Hims & Hers Health in the fourth quarter worth approximately $11,187,000. Finally, Aquatic Capital Management LLC purchased a new stake in Hims & Hers Health in the third quarter worth approximately $5,233,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $32.69 on Tuesday. The company’s fifty day moving average price is $30.21 and its 200-day moving average price is $26.34. The stock has a market cap of $7.57 billion, a PE ratio of -363.18, a price-to-earnings-growth ratio of 92.42 and a beta of 2.35. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, equities analysts expect that Hims & Hers Health will post 0.03 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.